NASDAQ:LXRX

Lexicon Pharmaceuticals Competitors

$5.37
-0.06 (-1.10 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.32
Now: $5.37
$5.52
50-Day Range
$5.43
MA: $6.65
$7.75
52-Week Range
$1.03
Now: $5.37
$9.65
Volume739,200 shs
Average Volume4.67 million shs
Market Capitalization$775.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09

Competitors

Lexicon Pharmaceuticals (NASDAQ:LXRX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying LXRX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Lexicon Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Amgen0101402.58

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Amgen.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Amgen$23.36 billion6.14$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Amgen29.42%95.55%15.52%

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amgen beats Lexicon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Gilead Sciences191402.54

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Gilead Sciences has a consensus price target of $97.2308, suggesting a potential upside of 49.33%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Gilead Sciences.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60

Gilead Sciences has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Gilead Sciences5.48%37.77%12.76%

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Lexicon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Vertex Pharmaceuticals042112.88

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 37.39%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73

Vertex Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Vertex Pharmaceuticals38.51%28.55%20.68%

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Lexicon Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Regeneron Pharmaceuticals051412.80

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Regeneron Pharmaceuticals has a consensus price target of $637.2083, suggesting a potential upside of 34.10%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13

Regeneron Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Lexicon Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Biogen5141202.23

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Biogen has a consensus price target of $303.5517, suggesting a potential upside of 13.19%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Biogen$14.38 billion2.84$5.89 billion$33.577.99

Biogen has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Lexicon Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Alexion Pharmaceuticals017512.30

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 0.74%. Given Lexicon Pharmaceuticals' higher possible upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Lexicon Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91

Alexion Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats Lexicon Pharmaceuticals on 12 of the 15 factors compared between the two stocks.


Lexicon Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95-0.8%$143.35 billion$23.36 billion20.08
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11-0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35-1.4%$55.46 billion$4.16 billion26.94Analyst Report
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17-0.3%$50.91 billion$7.86 billion17.37
Biogen logo
BIIB
Biogen
1.9$268.17-0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01-0.3%$34.08 billion$4.99 billion36.22
Seagen logo
SGEN
Seagen
1.7$142.85-1.1%$25.90 billion$916.71 million56.24Insider Selling
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.54-2.4%$21.23 billion$876.29 million-56.81
Incyte logo
INCY
Incyte
1.9$79.96-1.1%$17.58 billion$2.16 billion-50.93
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23-3.1%$16.22 billion$219.75 million-17.65
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
Novavax logo
NVAX
Novavax
1.6$179.74-1.9%$13.28 billion$18.66 million-34.43
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
Exelixis logo
EXEL
Exelixis
1.9$23.12-1.0%$7.21 billion$967.78 million48.17
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16-1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Codexis logo
CDXS
Codexis
1.1$24.00-2.6%$1.55 billion$68.46 million-68.57
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Revision
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71-1.4%$820.43 million$3.57 million-9.29
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19
Agenus logo
AGEN
Agenus
1.6$2.78-0.4%$570.05 million$150.05 million-2.55
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Unusual Options Activity
Gap Down
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Insider Buying
High Trading Volume
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.